AU2014329403B2 - Methods of detection and removal of rhabdoviruses from cell lines - Google Patents

Methods of detection and removal of rhabdoviruses from cell lines Download PDF

Info

Publication number
AU2014329403B2
AU2014329403B2 AU2014329403A AU2014329403A AU2014329403B2 AU 2014329403 B2 AU2014329403 B2 AU 2014329403B2 AU 2014329403 A AU2014329403 A AU 2014329403A AU 2014329403 A AU2014329403 A AU 2014329403A AU 2014329403 B2 AU2014329403 B2 AU 2014329403B2
Authority
AU
Australia
Prior art keywords
rhabdovirus
rna
sample
seq
rnase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014329403A
Other languages
English (en)
Other versions
AU2014329403A1 (en
Inventor
Joel Haynes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Vaccines Inc
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of AU2014329403A1 publication Critical patent/AU2014329403A1/en
Application granted granted Critical
Publication of AU2014329403B2 publication Critical patent/AU2014329403B2/en
Priority to AU2020294216A priority Critical patent/AU2020294216B2/en
Priority to AU2022259826A priority patent/AU2022259826B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20051—Methods of production or purification of viral material
    • C12N2760/20052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2014329403A 2013-10-03 2014-10-03 Methods of detection and removal of rhabdoviruses from cell lines Active AU2014329403B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2020294216A AU2020294216B2 (en) 2013-10-03 2020-12-22 Methods of detection and removal of rhabdoviruses from cell lines
AU2022259826A AU2022259826B2 (en) 2013-10-03 2022-10-27 Methods of detection and removal of rhabdoviruses from cell lines

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361886438P 2013-10-03 2013-10-03
US61/886,438 2013-10-03
PCT/US2014/059060 WO2015051255A1 (en) 2013-10-03 2014-10-03 Methods of detection and removal of rhabdoviruses from cell lines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020294216A Division AU2020294216B2 (en) 2013-10-03 2020-12-22 Methods of detection and removal of rhabdoviruses from cell lines

Publications (2)

Publication Number Publication Date
AU2014329403A1 AU2014329403A1 (en) 2016-05-05
AU2014329403B2 true AU2014329403B2 (en) 2020-10-08

Family

ID=52779185

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2014329403A Active AU2014329403B2 (en) 2013-10-03 2014-10-03 Methods of detection and removal of rhabdoviruses from cell lines
AU2020294216A Active AU2020294216B2 (en) 2013-10-03 2020-12-22 Methods of detection and removal of rhabdoviruses from cell lines
AU2022259826A Active AU2022259826B2 (en) 2013-10-03 2022-10-27 Methods of detection and removal of rhabdoviruses from cell lines

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2020294216A Active AU2020294216B2 (en) 2013-10-03 2020-12-22 Methods of detection and removal of rhabdoviruses from cell lines
AU2022259826A Active AU2022259826B2 (en) 2013-10-03 2022-10-27 Methods of detection and removal of rhabdoviruses from cell lines

Country Status (9)

Country Link
US (5) US10501500B2 (enExample)
EP (1) EP3052631B1 (enExample)
JP (6) JP2016533172A (enExample)
KR (2) KR102649950B1 (enExample)
CN (1) CN106103720A (enExample)
AU (3) AU2014329403B2 (enExample)
CA (1) CA2926225A1 (enExample)
SG (3) SG11201602585XA (enExample)
WO (1) WO2015051255A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012103541A2 (en) * 2011-01-28 2012-08-02 Schlumberger Canada Limited Pipe damage interpretation system
WO2015051255A1 (en) 2013-10-03 2015-04-09 Takeda Vaccines, Inc. Methods of detection and removal of rhabdoviruses from cell lines
JP6893174B2 (ja) * 2015-01-16 2021-06-23 タケダ ワクチン，インコーポレイテッド 粒子に含まれる逆転写酵素活性の検出
HUE051827T2 (hu) 2015-03-05 2021-03-29 Boehringer Ingelheim Animal Health Usa Inc Marker-rendszer, különösen baculovírus által expresszált alegység-antigénekhez
CN104962580B (zh) * 2015-06-30 2018-04-27 浙江大学 一种重组植物弹状病毒载体及其构建方法
EP4105321A1 (en) * 2015-11-01 2022-12-21 Glycobac, LLC Virus-free cell lines and methods for obtaining same
CN109182277B (zh) * 2018-09-07 2021-05-07 中国水产科学研究院长江水产研究所 一种黄鳝弹状病毒CrERV及RT-PCR检测引物及应用
EP3887756B1 (en) 2018-12-02 2025-07-23 Gentex Corporation Systems, devices and methods for micro-vibration data extraction using a time of flight (tof) imaging device
EP4100420A1 (en) 2020-02-06 2022-12-14 Boehringer Ingelheim Vetmedica GmbH Polypeptides useful for detecting anti-rhabdovirus antibodies
EP4103699A1 (en) * 2020-02-10 2022-12-21 BioMarin Pharmaceutical Inc. Virus-free cell cultures
CN114686599A (zh) * 2020-12-30 2022-07-01 北京五加和基因科技有限公司 宿主昆虫细胞dna残留含量定量检测方法及试剂盒
EP4340874A1 (en) 2021-05-21 2024-03-27 Takeda Vaccines, Inc. Solid composition, freeze-drying method and glass vial
CN115491377B (zh) * 2021-06-18 2025-09-16 北京三诺佳邑生物技术有限责任公司 一种诱导rna干扰和降低并清除细胞中病毒污染的核苷酸序列及应用
CN116731953A (zh) * 2022-03-01 2023-09-12 成都威斯克生物医药有限公司 弹状病毒阴性草地贪夜蛾昆虫细胞株及其筛选、鉴定和应用
CN118547114A (zh) * 2024-05-29 2024-08-27 长春生物制品研究所有限责任公司 一种用于Sf弹状病毒荧光定量检测的引物、探针、试剂盒及方法
CN120700212A (zh) * 2025-08-27 2025-09-26 北京昭衍生物技术有限公司 一种用于检测弹状病毒的qPCR引物探针组合物、试剂盒及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5024947A (en) * 1987-07-24 1991-06-18 Cetus Corporation Serum free media for the growth on insect cells and expression of products thereby

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457189A (en) * 1989-12-04 1995-10-10 Isis Pharmaceuticals Antisense oligonucleotide inhibition of papillomavirus
US5646262A (en) * 1994-07-28 1997-07-08 Georgetown University Antisense oligonucleotides against hepatitis B viral replication
US6103526A (en) 1998-10-08 2000-08-15 Protein Sciences Corporation Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using
DK1561756T3 (en) * 2002-09-11 2016-02-15 Chugai Pharmaceutical Co Ltd PROCEDURE FOR CLEANING PROTEIN.
JP2005168485A (ja) * 2003-11-20 2005-06-30 Tsutomu Suzuki ｓｉＲＮＡの設計方法
PL2601970T3 (pl) 2006-09-29 2017-07-31 Takeda Vaccines, Inc. Preparaty szczepionki przeciw norowirusowi
US8481693B2 (en) 2007-03-14 2013-07-09 Takeda Vaccines (Montana), Inc. Virus like particle purification
WO2009006450A1 (en) * 2007-06-29 2009-01-08 Boston Biomedical, Inc. Bacteria-mediated gene modulation via microrna machinery
US10130696B2 (en) 2007-09-18 2018-11-20 Takeda Vaccines, Inc. Method of conferring a protective immune response to norovirus
EP2324113B8 (en) 2008-08-08 2018-04-04 Takeda Vaccines, Inc. Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity
CA2739077A1 (en) * 2008-10-20 2010-04-29 Robert K. Hickman Antibodies that bind to il-18 and methods of purifying the same
US9056896B2 (en) * 2009-03-27 2015-06-16 Asahi Kasei Medical Co., Ltd. Method for removing viruses from high concentration monoclonal antibody solution
WO2012083363A1 (en) * 2010-12-22 2012-06-28 Murdoch Childrens Research Institute A method of treatment
KR102096937B1 (ko) 2011-07-11 2020-04-03 다케다 백신즈 인코포레이티드 비경구 노로바이러스 백신 제제
CN102605106B (zh) * 2012-03-29 2013-09-04 浙江省检验检疫科学技术研究院 蚕微孢子虫、核型多角体病毒和浓核病毒的三重荧光pcr检测方法及试剂盒和引物、探针
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
WO2015051255A1 (en) 2013-10-03 2015-04-09 Takeda Vaccines, Inc. Methods of detection and removal of rhabdoviruses from cell lines
EP4105321A1 (en) 2015-11-01 2022-12-21 Glycobac, LLC Virus-free cell lines and methods for obtaining same
CN114807009A (zh) 2022-03-28 2022-07-29 成都纳微金生物技术有限公司 一种不依赖血清的无弹状病毒污染的sf9细胞株、筛选方法及应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5024947A (en) * 1987-07-24 1991-06-18 Cetus Corporation Serum free media for the growth on insect cells and expression of products thereby

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Bombyx mori mRNA, clone: bmnc30d11, 3' end sequence, expressed in BmNPV-infected BmN cells.", EMBL, (2010-06-25), Database accession no. FY063436, URL: EBI *
J. Gen. Virol., (2011), Vol. 92, pages 200 - 203 *

Also Published As

Publication number Publication date
CN106103720A (zh) 2016-11-09
EP3052631B1 (en) 2019-08-07
AU2022259826A1 (en) 2023-01-19
US20230303633A1 (en) 2023-09-28
AU2022259826B2 (en) 2025-01-02
KR20210154988A (ko) 2021-12-21
JP2022009010A (ja) 2022-01-14
AU2014329403A1 (en) 2016-05-05
WO2015051255A1 (en) 2015-04-09
SG11201602585XA (en) 2016-05-30
JP2024050747A (ja) 2024-04-10
AU2020294216B2 (en) 2022-11-24
US20250109172A1 (en) 2025-04-03
AU2020294216A1 (en) 2021-01-28
EP3052631A4 (en) 2017-06-14
US12018052B2 (en) 2024-06-25
JP2023126495A (ja) 2023-09-07
US11286282B2 (en) 2022-03-29
SG10201802772YA (en) 2018-05-30
JP7191175B2 (ja) 2022-12-16
US12006341B2 (en) 2024-06-11
JP2016533172A (ja) 2016-10-27
KR20160062049A (ko) 2016-06-01
EP3052631A1 (en) 2016-08-10
KR102474663B1 (ko) 2022-12-07
JP2023024506A (ja) 2023-02-16
KR102649950B1 (ko) 2024-03-22
JP2020036613A (ja) 2020-03-12
US20200190146A1 (en) 2020-06-18
US20220213150A1 (en) 2022-07-07
US10501500B2 (en) 2019-12-10
CA2926225A1 (en) 2015-04-09
SG10202107054TA (en) 2021-08-30
US20160244487A1 (en) 2016-08-25
US12479891B2 (en) 2025-11-25

Similar Documents

Publication Publication Date Title
AU2020294216B2 (en) Methods of detection and removal of rhabdoviruses from cell lines
JP6907202B2 (ja) ウイルス由来の治療剤を解析する方法
Luo et al. Amino acid mutation in position 349 of glycoprotein affect the pathogenicity of rabies virus
EP3121268B1 (en) Methods for purification of a virus produced in vitro and clearance assay for the virus
HK1227433A1 (en) Methods of detection and removal of rhabdoviruses from cell lines
HK1227433B (en) Methods of detection and removal of rhabdoviruses from cell lines
JP6893174B2 (ja) 粒子に含まれる逆転写酵素活性の検出
Marquardt et al. Aims of the FMDV‐specific RT‐PCR as it is performed at the BFAV, tuebingen laboratory
HK1231118B (en) Methods for purification of a virus produced in vitro and clearance assay for the virus
HK1231118A1 (en) Methods for purification of a virus produced in vitro and clearance assay for the virus

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)